Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 4.4% - Still a Buy?

Key Points

• Maze Therapeutics' stock price increased by 4.4% to $27.34 amid a trading volume decline to approximately 153,734 shares, significantly lower than its average daily volume.
• Various analysts have upgraded Maze Therapeutics, with notable raises in price targets: BTIG Research increased its target from $30 to $37, while HC Wainwright set a target at $50, contributing to a consensus "Buy" rating for the stock.
• A recent insider transaction saw Director Richard H. Scheller sell over 20,000 shares at an average price of $22.37, totaling nearly $464,000, indicating potential changes in insider sentiment.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s stock price rose 4.4% during trading on Thursday . The company traded as high as $27.36 and last traded at $27.34. Approximately 153,734 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 286,424 shares. The stock had previously closed at $26.18.

Analyst Upgrades and Downgrades

MAZE has been the subject of a number of analyst reports. Wall Street Zen raised shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. BTIG Research raised their price objective on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a "buy" rating in a research note on Friday, September 12th. Guggenheim raised their price objective on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a "buy" rating in a research note on Monday, September 15th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Maze Therapeutics in a research report on Thursday, September 18th. Finally, Wedbush assumed coverage on shares of Maze Therapeutics in a research note on Tuesday, July 8th. They set an "outperform" rating and a $17.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $32.67.

Maze Therapeutics Stock Performance

The company's fifty day moving average is $16.69 and its 200-day moving average is $12.94.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of Maze Therapeutics stock in a transaction on Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its position in Maze Therapeutics by 452.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock valued at $57,000 after purchasing an additional 3,774 shares during the period. Frazier Life Sciences Management L.P. lifted its position in Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company's stock valued at $56,040,000 after purchasing an additional 438,274 shares during the period. Engineers Gate Manager LP acquired a new position in shares of Maze Therapeutics in the second quarter worth about $125,000. Bank of America Corp DE raised its position in shares of Maze Therapeutics by 33.6% in the second quarter. Bank of America Corp DE now owns 5,782 shares of the company's stock worth $71,000 after acquiring an additional 1,455 shares during the period. Finally, CW Advisors LLC acquired a new position in shares of Maze Therapeutics in the second quarter worth about $371,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.